AOTI (LSE:AOTI) shares gained 10.6% to 47.0p after the company published a study showing 64.8% complete healing with TWO2® therapy.
The study, which the company says shows superior and more durable healing compared with population-based real-world data, covers a broad mix of wound types including diabetic foot ulcers, venous leg ulcers, arterial and atypical wounds and supports AOTI’s commercial technology offering of at-home topical wound oxygen therapy.
"This large real-world study demonstrated significantly improved durable healing and lower wound recurrence with the use of TWO2® therapy in complex comorbid patient populations," Dr. Mike Griffiths, Chief Executive Officer, said.
The paper reports 64.8% complete healing (n=2,027), a 2.7% retreatment rate (n=54) over a mean 13.9 months follow-up, and low rates of hospitalisation and amputation of 3.7% (n=115) and 6.1% (n=191) respectively.
AOTI compared these outcomes with US Wound Registry figures cited in the paper (DFUs 45% healing, VLUs 57% healing) and with earlier real-world DFU data that reported substantially higher hospitalisation and amputation rates in patients not treated with TWO2®.
